A Clinical trial to study the effect of the drug KADIKKARA CHENDURAM in patients having Irritable Bowel Syndrome

Evaluation of KADIKKARA CHENDURAM for MAGAA VATHAM (Irritable Bowel Syndrome)- An Open Clincal study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016633

Enrollment

Registered

2018-12-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K90-K95- Other diseases of the digestive system

Interventions

Intervention1: KADIKKARA CHENDURAM: KADIKKARA CHENDURAM is administrated orally at the dose of 32mg twice a day with Honey as a adjuvant for 14 days Control Intervention1: Not applicable: NIL

Eligibility

Inclusion criteria

Inclusion criteria: IBS-Diarrhoea predominant Abdominal pain or discomfort often exacerbated by eating Abdominal distension and increased belching Dyspepsia, Heartburn, Nausea

Exclusion criteria

Exclusion criteria: Post infectious IBS (Campylobacter, Salmonella, and Shigella) Inflammatory Bowel Disease(IBD) Ulcerative colitis Crohnâ??s disease Microscopic colitis Diverticular Disease Pregnant women Patients who are undergone for psychiatric treatment. Will be excluded clinically or based on available medical reports

Design outcomes

Primary

Measure	Time frame
The outcome is mainly assessed by Reduction in clinical symptoms by comparing before and after treatment. Timepoint: 14 days	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR ZAFIROON NISA W

GOVERNMENT SIDDHA MEDICAL COLLEGE ARUMBAKKAM CHENNAI

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026